NASDAQ:ADIL - Adial Pharmaceuticals Stock Price, Forecast & News

Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."

Adial Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Adial Pharmaceuticals.

2 brokerages have issued 12 month price targets for Adial Pharmaceuticals' stock. Their forecasts range from $5.00 to $5.00. On average, they expect Adial Pharmaceuticals' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 127.3% from the stock's current price. View Analyst Price Targets for Adial Pharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adial Pharmaceuticals.

Press coverage about ADIL stock has been trending negative on Monday, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Adial Pharmaceuticals earned a news sentiment score of -2.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Adial Pharmaceuticals.

Adial Pharmaceuticals saw a decrease in short interest in November. As of November 15th, there was short interest totalling 44,900 shares, a decrease of 9.7% from the October 31st total of 49,700 shares. Based on an average daily volume of 41,500 shares, the short-interest ratio is currently 1.1 days. Currently, 0.7% of the company's stock are short sold. View Adial Pharmaceuticals' Current Options Chain.

Some companies that are related to Adial Pharmaceuticals include Inflarx (IFRX), Aduro BioTech (ADRO), ESSA Pharma (EPIX), Synlogic (SYBX), CTI BioPharma (CTIC), Millendo Therapeutics (MLND), Immunic (IMUX), vTv Therapeutics (VTVT), Scpharmaceuticals (SCPH), Cumberland Pharmaceuticals (CPIX), Elite Pharmaceuticals (ELTP), Chembio Diagnostics (CEMI), Vaccinex (VCNX), Aclaris Therapeutics (ACRS) and Selecta Biosciences (SELB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Tandem Diabetes Care (TNDM), Adobe (ADBE), Advanced Micro Devices (AMD), New Age Beverages (NBEV), Zynerba Pharmaceuticals (ZYNE), Canopy Growth (CGC), Altria Group (MO) and AcelRx Pharmaceuticals (ACRX).

(ADIL) raised $8 million in an initial public offering (IPO) on Friday, July 27th 2018. The company issued 1,500,000 shares at $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager.

Shares of ADIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADIL stock can currently be purchased for approximately $2.20.

Adial Pharmaceuticals has a market capitalization of $22.70 million. Adial Pharmaceuticals employs 3 workers across the globe.View Additional Information About Adial Pharmaceuticals.

The official website for Adial Pharmaceuticals is http://www.adialpharma.com/.

Adial Pharmaceuticals' mailing address is 1001 RESEARCH PARK BLVD. SUITE 100, CHARLOTTESVILLE VA, 22911. The company can be reached via phone at 434-422-9800 or via email at [email protected]